Novocure device fails to improve brain cancer patients’ survival in phase 3 test
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.